Family of large biological molecules
POPULARITY
Categories
108 episodes with RNA
65 episodes with RNA
76 episodes with RNA
25 episodes with RNA
142 episodes with RNA
27 episodes with RNA
28 episodes with RNA
42 episodes with RNA
26 episodes with RNA
14 episodes with RNA
15 episodes with RNA
19 episodes with RNA
10 episodes with RNA
24 episodes with RNA
11 episodes with RNA
36 episodes with RNA
11 episodes with RNA
13 episodes with RNA
9 episodes with RNA
10 episodes with RNA
28 episodes with RNA
16 episodes with RNA
16 episodes with RNA
11 episodes with RNA
7 episodes with RNA
6 episodes with RNA
8 episodes with RNA
7 episodes with RNA
9 episodes with RNA
11 episodes with RNA
11 episodes with RNA
9 episodes with RNA
6 episodes with RNA
12 episodes with RNA
14 episodes with RNA
18 episodes with RNA
6 episodes with RNA
4 episodes with RNA
10 episodes with RNA
162 episodes with RNA
4 episodes with RNA
7 episodes with RNA
5 episodes with RNA
4 episodes with RNA
12 episodes with RNA
10 episodes with RNA
150 episodes with RNA
11 episodes with RNA
5 episodes with RNA
8 episodes with RNA
8 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
6 episodes with RNA
10 episodes with RNA
6 episodes with RNA
4 episodes with RNA
6 episodes with RNA
7 episodes with RNA
6 episodes with RNA
7 episodes with RNA
8 episodes with RNA
5 episodes with RNA
3 episodes with RNA
7 episodes with RNA
6 episodes with RNA
3 episodes with RNA
15 episodes with RNA
4 episodes with RNA
5 episodes with RNA
8 episodes with RNA
4 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
8 episodes with RNA
3 episodes with RNA
7 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
7 episodes with RNA
8 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
6 episodes with RNA
7 episodes with RNA
19 episodes with RNA
5 episodes with RNA
14 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
3 episodes with RNA
4 episodes with RNA
10 episodes with RNA
6 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
5 episodes with RNA
5 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
3 episodes with RNA
12 episodes with RNA
6 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
2 episodes with RNA
3 episodes with RNA
3 episodes with RNA
8 episodes with RNA
5 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
6 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
4 episodes with RNA
3 episodes with RNA
8 episodes with RNA
3 episodes with RNA
3 episodes with RNA
2 episodes with RNA
4 episodes with RNA
3 episodes with RNA
Werbung *** Diese Folge wurde mit freundlicher Unterstützung der Firma Miltenyi Biotec produziert *** Zwei-gegen-Eins Interview mit Oliver Petters von Miltenyi Biotec über Spatial Biology Miltenyi Biotec wurde 1989 von Stefan Miltenyi gegründet und ist eines der ältesten und größten deutschen Unternehmen der Biotechnologie-Branche. Die Firma ist ein global agierendes Biotechnologie- und Biomedizin-Unternehmen und gilt als führender Anbieter von Produkten zur magnetischen Zellsortierung und -analyse (MACS). In unserem heutigen Zwei-gegen-Eins Interview geht es jedoch um Spatial Biology, über die wir mit Oliver Petters von Miltenyi Biotec sprechen durften. Spatial Biology, also die „Räumliche Biologie“ befasst sich mit der Untersuchung von Biomolekülen und Zellen in ihrem natürlichen dreidimensionalen Kontext. Sie umfasst verschiedene Ebenen der zellulären Auflösung, darunter die subzelluläre Lokalisierung von DNA, RNA und Proteinen, die Auflösung auf Einzelzellniveau und in situ-Kommunikation wie Zell-Zell-Interaktionen und Zellsignale, zelluläre Nachbarschaften, Regionen oder Mikroumgebungen und die Architektur und Organisation von Gewebe in Organen. Eine super spannende Methode…wie sie genau funktioniert, wie diese Technologie in den Alltag der Pathologie passt und warum wir mit Oliver auch über das Weltall sprechen, erfahrt ihr in dieser Folge. Klingt spannend? Dann schnell reingehört… Viel Spaß mit dieser innovativen Folge! Es ist übrigens die zweite von dreien…. Hier der link zur ersten Folge mit Stephan Werk von Miltenyi Biotec über die Lichtblattmikroskopie:(https://pathoaufsohr.podbean.com/e/zwei-gegen-eins-interview-mit-stephan-werk-von-miltenyi-biotec-uber-die-lichtblattmikroskopie/) …und hier der zu Miltenyi Biotec: (https://www.miltenyibiotec.com/DE-en/) Wir freuen uns über euer feedback. Kontakt: sven.perner@pathopodcast.de linkedin.com/in/prof-dr-med-sven-perner-6a771b48 christiane.kuempers@pathopodcast.de linkedin.com/in/pd-dr-med-christiane-charlotte-kümpers-279a382b8 Disclaimer: Der Podcast dient ausschließlich allgemeinen Informationszwecken. Die Informationen dieses Podcast sind kein Ersatz für eine professionelle medizinische oder psychologische Beratung, Diagnose oder Behandlung. Die Nutzung der Informationen oder von Materialien, die mit diesem Podcast verlinkt sind, erfolgt auf eigene Verantwortung. Bei gesundheitlichen Fragen oder Beschwerden sollte ein Arzt/eine Ärztin Ihres Vertrauens konsultiert werden.
Broadcast from KSQD, Santa Cruz on 10-30-2025: Dr. Dawn opens with Halloween-themed scary medical stories, beginning with food toxins lurking in refrigerators and pantries. She explains how molds on grains and nuts, particularly Aspergillus species, produce aflatoxins that bind to DNA and cause liver cancer, making peanuts especially risky. Fusarium on wheat produces trichothecenes and fumonisins damaging cell membranes. Penicillium molds on fruits like apples produce patulin creating reactive oxygen species that harm organs. She advises discarding soft moldy foods entirely since fungal hyphae penetrate deeply, while hard cheeses can have moldy portions cut away. Meat spoilage involves bacteria producing cadaverine and putrescine, with E. coli, Campylobacter, Salmonella, and Clostridium causing severe illness through heat-stable toxins. A caller asks about yogurt-covered peanuts tasting rancid and confirms Botox contains botulinum toxin A in different salt forms, used medically for migraines, hyperhidrosis, and strabismus. The caller also describes paper-thin skin on sun-exposed forearms that bleeds easily. Dr. Dawn explains UV radiation damages collagen and elastin, making blood vessels vulnerable to shear forces. She recommends topical vitamin K products like Dermal K and protective lycra sleeves or gardening gauntlets to prevent injuries, emphasizing the need for annual dermatologic exams after extensive sun exposure. An emailer asks about RSV vaccine recommendations before overseas travel. Dr. Dawn disagreed with the couple's physician, citing US Preventive Services Task Force guidelines recommending RSV vaccination for all adults 60 and older, plus those 50+ with chronic conditions. She discusses FDA-approved home testing options including the PIXEL by LabCorp test for COVID, flu, and RSV, and iHealth rapid tests. She notes RSV point-of-care tests are available to medical practitioners and recommends thorough vaccination before international trips. Dr. Dawn presents a frightening investigation into private equity hospital bankruptcies, focusing on Steward Healthcare's 31 hospitals and Prospect's 16 facilities. Private equity firm Cerberus earned $700 million while Steward 650 documented incidents of deficient care including deaths. One woman died from hemorrhage after vendors repossessed equipment due to unpaid bills. She explains the shell game where companies sell hospital land to Medical Properties Trust, forcing new operators to pay rent while private equity extracts profits. The Brookings Institution study reveals systematic prioritization of investor returns over patient care, with courts failing to prevent these practices despite some states passing protective legislation. She discusses stillbirth rates being significantly underreported, with Harvard research showing actual rates of 1 in 147 pregnancies versus CDC's 1 in 175, worsening to 1 in 95 for black families. Over 70% involved known risks like obesity or diabetes, but 30% had no identifiable factors. Dr. Dawn emphasizes unconscious bias in medicine where women's complaints are dismissed, particularly affecting women of color and non-English speakers, noting both patient and provider biases require training to address. Dr. Dawn warns about HPV-related oral squamous cell carcinoma in young men, explaining that changing sexual practices over 30 years have created new transmission routes from genitals to mouth. Major risk factors include smokeless tobacco and hard alcohol which damage DNA. She mentions newly available saliva tests for persistent HPV detection, recommending risk factor reduction for positive cases. She concludes optimistically with a breakthrough Huntington's disease treatment using microRNA molecule AMT-130 delivered via virus to brain striatum. The treatment mirrors toxic Huntington protein's RNA, creating double-stranded structures cells destroy, preventing toxic protein accumulation. The three-year trial of 29 patients showed 75% slowing of disease progression with few side effects, offering hope for 100,000 Americans carrying the mutation, including 40,000 with current symptoms.
Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Download the transcript here
Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Listen to the podcast here
On this week's episode, Daphne Zohar, Bruce Booth, Sam Fazeli, Brian Skorney, Yaron Werber, and Eric Schmidt kick off with market updates, noting that the XBI is showing signs of a sustainable recovery after years of underperformance and highlighting that the IPO market is likely closed for the remainder of the year, but note optimism for early 2026. In deal news, Novartis' $12B acquisition of Avidity is spotlighted as an unprecedented move for a company yet to read out Phase 3 data. The co-hosts also speculate on what this acquisition could mean for Dyne Therapeutics, has a similar RNA-based pipeline in rare muscle disease. Next, Daphne highlights that some of the biggest M&A deals of the year have come from women-led companies - including Avidity. The conversation then shifts to Novo Nordisk's surprise $9Bbid for Metsera, which challenges Pfizer's existing $7.3B deal and raises questions about Novo's intentions. In policy news, manufacturing issues at Novo's Catalent Indiana facility and the impact on the sector are mentioned. The episode concludes with a group discussion around Bruce's lessons from his 20 years in early-stage biotech. *This episode aired on October 31, 2025.
00:47 How bowhead whales live so longResearchers have uncovered a protein that enhances DNA repair and may explain how bowhead whales can live more than 200 years. The protein, cold-induced RNA-binding protein, was shown to enhance repair of double stranded DNA breaks, a particularly troublesome kind of damage. The team showed that this protein could also extend the lives of Drosophila flies and enhance repair in human cells. More needs to be understood about how this protein works, but the researchers hope that it could, one day, help prevent cancer and ageing in humans.Research Article: Firsanov et al.News: This whale lives for centuries: its secret could help to extend human lifespan11:22 Research HighlightsA precise way to grow crystals, with lasers — plus, the specialist organ that allows stinkbugs to protect their eggs from wasps.Research Highlight: How to grow crystals when and where you want themResearch Highlight: Stinkbug ‘ear' actually hosts parasite-fighting fungi13:31 An antivenom against a broad range of snakebitesResearchers have used ‘nanobodies' to create an antivenom that works against 17 snake species' venom. Snakebites kill millions each year, so getting the right antivenom can be life or death. But they are difficult to produce and often are very specific. Now, using nanobodies from llamas, researchers created an antivenom against a broad range of snake species' venom. The new antivenom can now even be produced without the llamas, and the team hope it will pave the way for a more universal antivenom.Research Article: Ahmadi et al.Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped. The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies. Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve. On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space. BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next. Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating.
Novartis' biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the $12 billion deal for Avidity in the context of Novartis' recent acquisitions and the antibody-oligonucleotide conjugate platform it is gaining.The team dives into RNA versus DNA modalities, noting antisense and siRNA approaches appear to be gaining traction with major pharmas as traditional gene therapy and gene editing approaches hit rocky times. Still, they note hopeful progress among base editing therapies given the promising early track records of over a dozen base editors in the clinic. They also discuss BioCentury's conversation with base editing inventor David Liu; Alkermes' $2.1 billion acquisition of Avadel; and β-catenin data from Parabilis. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657412#AntibodyOligonucleotideConjugates #RNAtherapeutics #BaseEditing #MuscularDystrophy #WntPathway #BetaCatenin #Orexin2Receptor #PrecisionMedicine00:01 - Sponsor Message: Evotec 02:04 - 12th China Healthcare Summit08:11 - Novartis' $12B Deal16:58 - Alkermes M&A20:01 - David Liu Base Editing25:02 - Parabilis' DataTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show
Varroa mites remain the most destructive pest facing honey bees today—but a revolutionary new treatment may finally shift the balance. In this episode, Jeff Ott and Dr. Becky Masterman welcome Adam Pachl, North American Technical Manager for Bee Health at GreenLight Biosciences, to discuss Norroa, the first EPA-approved dsRNA-based treatment for Varroa mites. Norroa introduces a fundamentally new approach: instead of killing mites outright, it prevents them from reproducing. Adam explains how this RNA interference (RNAi) technology works at the molecular level, blocking the mites' ability to lay viable eggs without harming honey bees or other organisms. He also shares insights from years of field research, including trials across five U.S. states that demonstrated dramatic improvements in colony survival and mite suppression. Becky and Jeff explore the implications of this technology for beekeepers of all scales—from hobbyists managing a few hives to large-scale commercial operations—and how Norroa fits into an integrated pest management strategy. The discussion covers everything from timing of application, compatibility with other treatments, and safety testing, to potential future uses of RNAi against pests like Tropilaelaps. For the first time in decades, beekeepers may have a tool that targets Varroa precisely and safely—without collateral damage to the bees they're fighting to protect. Websites from the episode and others we recommend: GreenLight Biosciences. “GreenLight Biosciences Launches Norroa, the First RNA-Based Treatment for Varroa Mites.” 25 Sep 2025. https://www.greenlightbiosciences.com/articles/greenlight-biosciences-launches-norroa-the-first-rna-based-treatment-for-varroa-mites GreenLight Biosciences. “In the Pipeline: Protecting the Honeybee.” https://www.greenlightbiosciences.com/in-the-pipeline-protecting-the-honeybee GeneOnline. “EPA Registers Norroa as First RNA-Based Treatment for Varroa Mites Threatening Honeybee Populations.” 25 Sept 2025. https://www.geneonline.com/epa-registers-norroa-as-first-rna-based-treatment-for-varroa-mites-threatening-honeybee-populations Honey Bee Obscura Podcast: https://honeybeeobscura.com Project Apis m. (PAm): https://www.projectapism.org Honey Bee Health Coalition: https://honeybeehealthcoalition.org The National Honey Board: https://honey.com Honey Bee Obscura Podcast: https://honeybeeobscura.com Copyright © 2025 by Growing Planet Media, LLC ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com This episode is brought to you by Global Patties! Global offers a variety of standard and custom patties. Visit them today at http://globalpatties.com and let them know you appreciate them sponsoring this episode! Thanks to Bee Smart Designs as a sponsor of this podcast! Bee Smart Designs is the creator of innovative, modular and interchangeable hive systems made in the USA using recycled and American sourced materials. Bee Smart Designs - Simply better beekeeping for the modern beekeeper. Give your bees a boost with HiveAlive! Proven to increase bee health, honey yield, and overwinter survival, HiveAlive's unique formula includes seaweed, thyme, and lemongrass, making it easy to feed. Choose from HiveAlive's Fondant Patties, High-Performance Pollen Patties, or EZ Feed Super Syrup—ready-to-use options for busy beekeepers. Buy locally or online. HiveIQ is revolutionizing the way beekeepers manage their colonies with innovative, insulated hive systems designed for maximum colony health and efficiency. Their hives maintain stable temperatures year-round, reduce stress on the bees, and are built to last using durable, lightweight materials. Whether you're managing two hives or two hundred, HiveIQ's smart design helps your bees thrive while saving you time and effort. Learn more at HiveIQ.com. Thanks to Strong Microbials for their support of Beekeeping Today Podcast. Find out more about their line of probiotics in our Season 3, Episode 12 episode and from their website: https://www.strongmicrobials.com Thanks for Northern Bee Books for their support. Northern Bee Books is the publisher of bee books available worldwide from their website or from Amazon and bookstores everywhere. They are also the publishers of The Beekeepers Quarterly and Natural Bee Husbandry. _______________ We hope you enjoy this podcast and welcome your questions and comments in the show notes of this episode or: questions@beekeepingtodaypodcast.com Thank you for listening! Podcast music: Be Strong by Young Presidents; Epilogue by Musicalman; Faraday by BeGun; Walking in Paris by Studio Le Bus; A Fresh New Start by Pete Morse; Wedding Day by Boomer; Christmas Avenue by Immersive Music; Red Jack Blues by Daniel Hart; Original guitar background instrumental by Jeff Ott. Beekeeping Today Podcast is an audio production of Growing Planet Media, LLC ** As an Amazon Associate, we may earn a commission from qualifying purchases Copyright © 2025 by Growing Planet Media, LLC
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show
In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment.
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the five biggest stories in biohacking and health-tech — from genetic rejuvenation to your future digital twin — giving you the tools to live longer, perform better, and stay ahead of the curve.This episode covers:• Vitamin D as the Surprising “Anti-Aging Pill”A new five-year randomized study shows that daily 2,000 IU vitamin D supplementation slowed telomere shortening by 140 base pairs compared to placebo, translating to measurable gains in biological youth. Vitamin D isn't just for bones anymore — it's a foundational longevity molecule.Source: Science Daily — https://www.sciencedaily.com/releases/2025/10/251022023132.htm• The Supercentenarian Gene That Rejuvenates Old HeartsResearchers at the University of Bristol identified a gene variant, LAV-BPIFB4, common among people living past 100, that reversed cardiac aging in animal studies — restoring blood flow, heart strength, and tissue repair with a single treatment. It's a glimpse into how gene therapy could soon democratize superhuman longevity.Source: University of Bristol News — https://www.bristol.ac.uk/news/2025/october/progeria.html• FDA Closes the “GRAS” Loophole — Supplements Enter a New EraThe FDA just ended decades of self-certification for new dietary ingredients, requiring full agency review for anything entering the market. It's the biggest shakeup in supplement regulation in years — raising quality, accountability, and trust across the entire industry.Source: Mintz FDA Flux Newsletter — https://www.mintz.com/insights-center/viewpoints/2791/2025-10-16-fda-flux-october-2025-newsletter• Microbes That Trigger Autophagy — Your Gut as an Anti-Aging SwitchScientists at the University of Basel discovered that certain dietary bacteria containing double-stranded RNA can directly trigger autophagy, the body's built-in cell-recycling system. Fermented foods like kimchi, kefir, and sauerkraut may now be proven longevity tools for activating repair from the inside out.Source: University of Basel — https://www.unibas.ch/en/News-Events/News/Uni-Research/Longevity-research—Dietary-stress-supports-healthy-aging.htmlFurther reading: Neuroscience News — https://neurosciencenews.com/dietary-rna-cellular-aging-29757/• Your Medical Avatar Is Coming — The Digital Twin of YouForbes reports on the rise of personalized “medical avatars” — AI-powered digital twins built from your wearables and biometrics that can predict health risks, recommend interventions, and evolve alongside your biology. Doctors like Daniel Kraft call it generative health — a revolution in predictive medicine where your data literally becomes your doctor.Source: Forbes Innovation — https://www.forbes.com/sites/johnwerner/2025/10/21/wearables-ai-and-your-personal-medical-avatar/This is essential listening for fans of biohacking, human performance, functional medicine, and longevity sciencewho want real, actionable tools from Dave Asprey — the father of biohacking and founder of Bulletproof Coffee.With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your lifespan, and upgrade every system in your body and mind.New episodes drop every Tuesday, Thursday, Friday, and Sunday. Dave asks the questions no one else will — and gives you the science-backed tools to become stronger, smarter, and more resilient.Keywords: vitamin D longevity, telomeres, BPIFB4 gene, cardiac rejuvenation, supplement regulation, GRAS FDA, autophagy, microbiome, fermented foods, biohacking news, medical avatar, digital twin, predictive medicine, Daniel Kraft, quantum health, wearable AI, Dave Asprey, The Human UpgradeThank you to our sponsors! TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off.HeartMath | Go to https://www.heartmath.com/dave to save 15% off.Timestamps: 0:00 — Introduction0:18 — Story 1: Vitamin D & Telomeres1:02 — Story 2: Longevity Gene Therapy1:49 — Story 3: FDA Supplement Reform2:38 — Story 4: Gut Bacteria & Autophagy3:46 — Story 5: Medical Avatars4:53 — Weekly Protocol5:42 — OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
A doença hepática associada ao álcool é uma das principais causas de cirrose e insuficiência hepática no mundo. Mesmo após a interrupção do consumo, muitos pacientes não conseguem recuperar a função do fígado, o que reforça a necessidade de compreender como ocorre o processo de regeneração e por que ele falha em alguns casos.No novo episódio do podcast de Biotech and Health, Camila Pepe e Carolina Abelin conversam com o cirurgião Roberto Meirelles a respeito das descobertas científicas mais recentes sobre o papel do RNA na regeneração hepática. Ele explica como alterações inflamatórias provocadas pelo álcool podem comprometer a expressão genética e impedir que as células do fígado se recuperem.O médico destaca o potencial dessas pesquisas para identificar novos biomarcadores e orientar o desenvolvimento de terapias que possam restaurar a função hepática antes que o transplante se torne a única opção. A inteligência artificial, segundo ele, deve acelerar esse processo ao permitir análises mais rápidas e precisas de grandes volumes de dados biológicos.
2024 年的诺贝尔化学奖是颁给了三位在蛋白质结构预测和蛋白质设计领域作出开创性贡献的科学家。这标志着 AI 已经成为生命科学的核心工具 ，正在改变我们理解生命的方式和重塑药物研发的未来。 我们今天的嘉宾是深圳湾实验室的周耀旗教授，他是这场变革的亲历者和推动者之一。他最初在学术界专注于蛋白质结构预测，后来他敏锐地意识到 RNA 领域的潜力与挑战，将研究方向转向 RNA 结构预测。现在他又走上创业之路，带领团队开发 以 RNA 为靶点的小分子药物，探索如何将基础研究真正转化为新的疗法。今天的节目我们聊一聊作为蛋白质结构预测工具的 AlphaFold3，它的突破与局限在哪里？RNA为什么是新一代药物的重要靶点？以及 AI 在新药研发中的作用究竟是什么? 本期人物 周耀旗，深圳湾实验室资深研究员，砺博生物科学创始人 Yaxian，「科技早知道」主播 主要话题 [02:42] 为什么蛋白质结构如此重要？解析蛋白结构是理解生命机器的关键 [05:47] 蛋白质结构预测简史（超硬核）：基于模板 --> 碎片拼接 --> 二面角+距离预测 [14:26] 「1+2=3」：AlphaFold 革命性飞跃的背后 [17:40] 结构生物学家会不会被替代？聊聊 AlphaFold 还做不了的事 [23:26] RNA 结构预测为何更难？仅4个碱基，结构不稳定，已知数据稀缺 [29:24] 蛋白质只是「提线木偶」，RNA 才是「操纵者」 [31:56] 从靶向蛋白到靶向 RNA -- HIV蛋白酶抑制剂的成功和 KRAS 蛋白的「光滑锁眼」的难题 [35:49] 靶向 RNA 药物的里程碑：首个靶向 RNA 的小分子药利司扑兰（Risdiplam） [38:50] 在缺乏结构数据的情况下，如何开发靶向 RNA 的药物？ [43:06] AI 在新药研发中的真实作用：是加速器，而非革命 [45:39] AI for Science：摆脱数据依赖，回归物理，寻找分子世界的「牛顿定律」 延伸阅读 AlphaFold 由谷歌 DeepMind 开发的人工智能程序，AlphaFold2 在精准预测蛋白质三维结构方面取得革命性突破而闻名。AlphaFold3 将其能力扩展到了 RNA、DNA 等更多分子。 CASP (Critical Assessment of protein Structure Prediction) 国际蛋白质结构预测竞赛，每两年举办一次，是评估和检验全球结构预测方法水平的「奥林匹克」 KRAS 一种重要的信号蛋白，其基因突变是多种癌症（如胰腺癌、肺癌）的关键驱动因素。由于其蛋白质表面光滑，缺乏明显的结合位点，长期以来被认为是「不可成药」的靶点。 SMN 蛋白 (Survival of Motor Neuron protein) 即运动神经元存活蛋白，该蛋白的缺失会导致 脊髓性肌萎缩症 (SMA)。全球首个靶向 RNA 的药物就是通过调控 SMN 的 RNA 来提高其蛋白水平。 PCC (Pre-clinical Candidate) 即临床前候选化合物，指在早期发现阶段后，被选定进入正式的临床前研究（如动物安全性、药代动力学试验）的药物分子 幕后制作 监制：Yaxian 后期：迪卡 运营：George 设计：饭团 商业合作 声动活泼商业化小队，点击链接直达声动商务会客厅（https://sourl.cn/9h28kj ），也可发送邮件至 business@shengfm.cn 联系我们。 加入声动活泼 声动活泼目前开放商务合作实习生、社群运营实习生和 BD 经理等职位，详情点击招聘入口详情点击招聘入口 (https://eg76rdcl6g.feishu.cn/docx/XO6bd12aGoI4j0xmAMoc4vS7nBh?from=from_copylink) 关于声动活泼 「用声音碰撞世界」，声动活泼致力于为人们提供源源不断的思考养料。 我们还有这些播客：声动早咖啡 (https://www.xiaoyuzhoufm.com/podcast/60de7c003dd577b40d5a40f3)、声东击西 (https://etw.fm/episodes)、吃喝玩乐了不起 (https://www.xiaoyuzhoufm.com/podcast/644b94c494d78eb3f7ae8640)、反潮流俱乐部 (https://www.xiaoyuzhoufm.com/podcast/5e284c37418a84a0462634a4)、泡腾 VC (https://www.xiaoyuzhoufm.com/podcast/5f445cdb9504bbdb77f092e9)、商业WHY酱 (https://www.xiaoyuzhoufm.com/podcast/61315abc73105e8f15080b8a)、跳进兔子洞 (https://therabbithole.fireside.fm/) 、不止金钱 (https://www.xiaoyuzhoufm.com/podcast/65a625966d045a7f5e0b5640) 欢迎在即刻 (https://okjk.co/Qd43ia)、微博等社交媒体上与我们互动，搜索 声动活泼 即可找到我们。 期待你给我们写邮件，邮箱地址是：ting@sheng.fm 声小音 https://files.fireside.fm/file/fireside-uploads/images/4/4931937e-0184-4c61-a658-6b03c254754d/gK0pledC.png 欢迎扫码添加声小音，在节目之外和我们保持联系。 Special Guest: 周耀旗.
In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks.com, spoke with R. Nolan Townsend, MBA, CEO of Lexeo Therapeutics, a company developing gene therapies for cardiovascular diseases as well as CNS disorders including Alzheimer's disease. Lexeo recently announced a partnership to advance cardiac RNA therapeutics as well as $80 million in equity financing. Mr. Townsend has been CEO of Lexeo Therapeutics since 2020. He previously held senior leadership roles at Pfizer, including President of Rare Disease for both North America and International markets, and began his career in healthcare investment banking at Lehman Brothers. He currently also serves on several boards, including Arbor Biotechnologies, the Biotechnology Innovation Organization (BIO) and the Martha's Vineyard Museum. He is also a member of the New York City Economic Development Corporation's Life Sciences Advisory Council. Mr. Townsend received his MBA from the Harvard Business School and his Bachelor of Arts in Economics from the University of Pennsylvania. Tune in to hear how Lexeo is shaping the future of genetic medicines under Mr. Townsend's leadership. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Next-generation platforms and technologies are getting closer to cracking one of biopharma's biggest problems: delivering medicines, and mAbs in particular, to the brain. On the latest BioCentury This Week podcast, BioCentury's Selina Koch details the latest innovations in blood-brain-barrier shuttles and how the technologies could transform the treatment of neurological diseases.BioCentury's Lauren Martz discusses her conversation with Tony Wood, CSO of GSK, which included the pharma's strategy for indication expansion, why it prefers RNA modalities over AAV-based gene therapies, and how its quest for causal biology has evolved over the years.Washington Editor Steve Usdin discusses the first set of FDA's new commissioner's national priority review vouchers, and why the voucher program is unlikely to function as an incentive capable of steering future behavior. Usdin also discusses the potential impact of FDA staffing reductions on the sector. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657326#BloodBrainBarrier #Neurology #DrugDelivery #MonoclonalAntibodies #RNAtherapeutics #CausalBiology #FDA00:01 - Sponsor Message: Evotec01:57 - Brain Shuttles13:57 - GSK Q&A20:08 - FDA VouchersTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Más de dos mil mexicanos detenidos en EU desde el inicio de Trump Beca Universal Rita Cetina llegará a todas las primarias públicas en 2026Tormenta tropical Melissa se forma en el AtlánticoMás información en nuestro podcast
First up on the podcast, Contributing Correspondent Kai Kupferschmidt takes a trip to Svalbard, an Arctic archipelago where ancient RNA viruses may lie buried in the permafrost. He talks with host Sarah Crespi about why we only have 100 years of evolutionary history for viruses such as coronavirus and influenza, and what we can learn by looking deeper back in time. Next on the show, Nathalie Stroeymeyt, senior lecturer at the School of Biological Sciences at the University of Bristol, joins freelancer producer Elah Feder to talk about how humans aren't the only species that takes public health measures to stop outbreaks. To keep their colonies healthy when threatened with infectious disease, ants socially distance and even make architectural changes to their nests' organization. This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices
First up on the podcast, Contributing Correspondent Kai Kupferschmidt takes a trip to Svalbard, an Arctic archipelago where ancient RNA viruses may lie buried in the permafrost. He talks with host Sarah Crespi about why we only have 100 years of evolutionary history for viruses such as coronavirus and influenza, and what we can learn by looking deeper back in time. Next on the show, Nathalie Stroeymeyt, senior lecturer at the School of Biological Sciences at the University of Bristol, joins freelancer producer Elah Feder to talk about how humans aren't the only species that takes public health measures to stop outbreaks. To keep their colonies healthy when threatened with infectious disease, ants socially distance and even make architectural changes to their nests' organization. This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices
DNA doesn't “do", it instructs. In this episode of the Jack Westin MCAT Podcast, Mike and Molly walk through the central dogma, how we go from DNA → RNA → protein—and the regulation that makes different cells, well, different. Perfect for MCAT Bio/Biochem: we hit transcription, RNA processing, translation mechanics (A–P–E sites), start/stop codons, eukaryote vs. prokaryote differences, and multi-layered gene expression regulation (chromatin, transcription factors, miRNA/siRNA, ubiquitin, & more).
Using blood tests to look for cancer and cancer recurrence has been an area of active research for some time now, with a new study pointing to RNA rather than DNA for detection. William Nelson, director of the Kimmel Cancer … Can RNA provide a way to look for cancer recurrence? Elizabeth Tracey reports Read More »
RNA is easier to detect and points toward cancer activity better than DNA testing, a recent study concludes. Johns Hopkins Kimmel Cancer Center director William Nelson says there's an even more accurate method on the horizon. Nelson: Will RNA sequencing … Will RNA based tests form the basis for cancer screening and monitoring? Elizabeth Tracey reports Read More »
rWotD Episode 3084: RsaOG Welcome to random Wiki of the Day, your journey through Wikipedia's vast and varied content, one random article at a time.The random article for Monday, 13 October 2025, is RsaOG.RsaOG (an acronym for RNA S. aureus Orsay G) is a non-coding RNA that was discovered in the pathogenic bacteria Staphylococcus aureus N315 using a large scale computational screening based on phylogenetic profiling. It was first identified, but not named, in 2005. RsaOG has since been identified in other strains of Staphylococcus aureus under the name of RsaI, it has also been discovered in other members of the Staphylococcus genus (such as Staphylococcus carnosus) but in no other bacteria.The RsaOG gene is conserved in all Staphylococcaceae sequenced genomes, its secondary structure contains two highly conserved unpaired sequences which have the ability to form a pseudoknot. Northern blot experiments show that RsaOG is expressed in several S. aureus strains. Mapping of RsaOG ends indicates a size of 146 nucleotides in S. aureus. RsaOG ncRNA is thought to have trans-acting regulatory functions, possibly on fine tuning toxin production or aiding with invasion.This recording reflects the Wikipedia text as of 01:11 UTC on Monday, 13 October 2025.For the full current version of the article, see RsaOG on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Bluesky at @wikioftheday.com.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm long-form Patrick.
A little over a week ago, I spoke with Kevin McKernan about the paper he co-authored with Jessica Rose and David Speicher, looking at DNA contamination, including SV40 promoter-enhancer sequences, in the Pfizer and Moderna Covid vaccines. In that episode, I asked Kevin whether the paper is enough to demonstrate fraud on the part of the vaccine manufacturers. This is important, because if fraud can be shown, these companies lose their protection from legal liability.In this episode, I speak with Dr. Jessica Rose about the paper. She explains what is needed to prove fraud, and why that is challenging, but also explains why there is a strong case for it. We also talk about the corrupt nature of the justice system, her own calculation of VAERS underreporting, and the preprint by Kevin McKernan that had just come out, showing "Hyperstimulatory N⁶-methyladenine (m6A) in residual SV40 plasmid DNA in mRNA vaccines"—and possibly more evidence of fraud.We also talk a little about the meaning of life, and Jessica's cat shows up near the end. Again, the paper is here.Jessica's lay-person write-up of the paper is here.You can find Jessica on Substack, and on X.I spoke with Jessica back in May, about self-amplifying RNA.And my episode with Kevin, about the DNA contamination, is here.
Send us a textIn this episode of the Life Science Success Podcast my guest is Byron Purse, co-founder of AlidaBio and professor of chemistry at San Diego State University who is pioneering innovative approaches to studying RNA modifications. Byron brings a wealth of expertise in synthetic and natural nucleic acid modifications, with a passion for advancing biotechnology and human health through his groundbreaking research and entrepreneurial endeavors.00:00 Introduction to Life Science Success Podcast00:29 Meet Byron Purse: Professor and Co-Founder of AlidaBio01:05 Byron's Journey into Life Sciences03:10 From Academia to Entrepreneurship06:49 Founding AlidaBio: Vision and Mission08:59 Innovations in RNA Modifications23:09 Challenges and Successes in Developing the EpiPlex™ Platform28:44 Leadership and Inspiration35:00 Concerns and Future Outlook in Life Sciences43:02 Conclusion and Final Thoughts
AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025 Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation LKIN: https://www.linkedin.com/in/joankoerberwalker www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015), in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more. AZBio: Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed. AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community. Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity. Notes: Seg 1 Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion. Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024. AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday. Example of one of the many companies involved with AZ Bio week: CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun. NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research. Takes time to build a medical device type product, a few years to decades. Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help. $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory. Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years. Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups Seg 2 Examples of newer companies in biotech field – Neo clinical stage company dealing in heart health with aortic artery for the abdomen. Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages. Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control. AZ Bio has members that are in the bioscience industry with current companies AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education Patient is not only the client, but the purpose for why biotech companies exist Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017. Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025 https://www.azbio.org/azbw2025 Events Summary: Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style! Tuesday - Fundraising Fundraising Strategies for Life Science Startups A compelling narrative is crucial when you are fundraising and communicating with life science investors. This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup. Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world. Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards. Thursday - AZAdvances AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve. AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come. Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations. Friday - Voice of the Patient Patients are the reason we do what we do. Join the conversation on life science innovation from the patient perspective. Seg. 3 Best of AZ Bio clips: AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023 Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation Full Show: HERE Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc. He was also President of Sucampo Pharma Americas for 6 years. He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire). He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones. He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization. Aqualung Therapeutics Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension. Full Show: HERE Seg. 4 – Clips from: Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri - BRT S04 EP17 (179) 4-23-2023 Guest: Stephen Johnston Founding CEO, Calviri Inc. LKIN: HERE https://calviri.com/ Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin. Calviri Inc. We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine. Full Show: HERE ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023 Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI. https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/ https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery. Learn More The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions. Full Show: HERE Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE Biotech Shows: HERE AZ Tech Council Shows: https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023 ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT Thanks for Listening. Please Subscribe to the BRT Podcast. AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business. AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving. Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more… AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/ Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.
Blaise Agüera y Arcas's talk took us on a journey through What is Intelligence?, his groundbreaking new work connecting the evolutionary dots between life, computation, and symbiogenesis. He explores how, in our symbiotic world, things combine to make larger things all the time. We might think of humanity in terms of the individual — but we're already part of everything we're creating, which is in turn co-creating us. In the story of technology and humanity, are we distinct from the technologies that we make? Agüera y Arcas' cuts through the essentialist dogma with a functionalist view: Biological computing — computation through DNA, RNA, and proteins — is not a strange outcropping of life but its very nature. Blaise Agüera y Arcas is a VP and Fellow at Google, where he is the CTO of Technology & Society and founder of Paradigms of Intelligence (Pi). Pi is an organization working on basic research in AI and related fields, especially the foundations of neural computing, active inference, sociality, evolution, and artificial life. During his tenure at Google, Blaise has innovated on-device machine learning for Android and Pixel; invented Federated Learning, an approach to decentralized model training that avoids sharing private data; and founded the Artists + Machine Intelligence program.
Detectable HIV-1 RNA (viral load) can seem very worrisome for people living with HIV who are receiving antiretroviral therapy (ART) and for their healthcare professionals. Tune in to learn how Brian R. Wood, MD, differentiates HIV-1 RNA “blips” from persistent low-level viremia and from virologic failure, and how he handles each scenario.Presenter:Brian R. Wood, MDProfessor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonLink to full program: https://bit.ly/4nS7rYEGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This episode is sponsored by AGNTCY. Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. Can AI and RNA testing make illness optional? In this episode, Eye on AI host Craig S. Smith sits down with Naveen Jain, founder and CEO of Viome, to explore how RNA sequencing and artificial intelligence are transforming our understanding of chronic disease. Jain shares how a personal tragedy led him to launch Viome, a company on a mission to digitize the human body, predict illness before symptoms appear, and revolutionize healthcare. Together they discuss how Viome uses metatranscriptomics to analyze microbiome and human gene expression, what makes RNA a better indicator of health than DNA, and how large molecular AI models are paving the way for early detection of cancer, diabetes, Alzheimer's, and more. Jain also reveals his bold entrepreneurial framework—“Why this, why now, why me?”—and his belief that asking better questions is the real key to innovation. If you're interested in the intersection of AI, biotechnology, and human longevity, this is an episode you won't want to miss. Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI
Zakalený vzhled piva souvisí s kombinací proteinů z ječmene a polyfenolů z chmele. Když vědci přidali do ležáků extrakt z kvasinek navíc, pivo se nesrazilo. Roli v tom hraje spojení proteinů a kvasinkové RNA.
Zakalený vzhled piva souvisí s kombinací proteinů z ječmene a polyfenolů z chmele. Když vědci přidali do ležáků extrakt z kvasinek navíc, zákal nezmizel. Roli v tom hraje spojení proteinů a kvasinkové RNA.Všechny díly podcastu Laboratoř můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.
Most of us have had to take a few days off work or school because of the flu or Covid-19. But imagine being sick with Covid, not for a week or two, but for 750 days! That's exactly what happened to one patient described in a recent paper published in the Lancet (Characterisation of a persistent SARS-CoV-2 infection lasting more than 750 days in a person living with HIV: a genomic analysis - The Lancet Microbe). The patient, a 41-year-old man living with HIV, continuously tested positive for Covid-19 for 26 months. Because his HIV was poorly controlled, his immune system was compromised. He had also not been vaccinated against Covid-19 and never received antiviral treatment during his illness. While this was an incredibly tough experience for him personally, it offered researchers a rare chance to watch in real time how a virus can evolve inside a single human body. Over the course of 750 days, scientists collected eight samples from the patient. From these, they extracted viral RNA and sequenced the virus's genome. They found that: 68 new viral mutations appeared over time. 10 of these mutations were in the spike protein, the part of the virus that helps it enter human cells. Some of these matched the exact changes later seen in the highly transmissible Omicron variant. Even more concerning, one alteration made the virus better at evading immune responses. The important part of this study in that these mutations showed up in the patient months before they were detected spreading widely in the community. This suggests that long-term infections in immunocompromised people can act like mutation incubators, where the virus experiments with new tricks before releasing them into the wider population. This case highlights several important lessons: Persistent infections matter: They aren't just unusual cases. They can directly influence how viruses evolve and have a consequence on the rest of the world. High-risk patients need better support: Improved access to antiretroviral therapy for HIV, vaccination, and Covid-19 treatments can reduce the chances of these prolonged infections. Stopping variant incubation is key: By treating persistent infections early, we may be able to slow down or even prevent the emergence of dangerous new variants. This story is a sobering reminder that pandemics don't just happen on a global stage, they can begin quietly, inside the body of a single individual. For scientists, these unusual cases are windows into viral evolution. For the rest of us, they underscore why protecting vulnerable groups isn't just compassionate, it's critical for everyone's health. LISTEN ABOVESee omnystudio.com/listener for privacy information.
Impact Video Ministries explains to us how we can know that god is real, and they are mostly length based reasons.Cards:Fact-Checking James Tour's Embarrassing Debate Performance:www.youtube.com/watch?v=YAm2W99Qm0oGod's "Perfect" Word has a LOT of Imperfections…:https://www.youtube.com/watch?v=_TVKrUWbvXQDesigns Need Designers, so EVERYTHING Is Designed!: https://www.youtube.com/watch?v=hPDm77oAXXUOriginal Video: https://tinyurl.com/2cyaq6djSources:Neutrino detector: https://tinyurl.com/hwlcvcqAbiogenesis through gradual evolution of autocatalysis into template-based replication: https://tinyurl.com/2359v3qaIdentifying the wide diversity of extraterrestrial purine and pyrimidine nucleobases in carbonaceous meteorites: https://tinyurl.com/yyqbrajwLife as a manifestation of the second law of thermodynamics: https://tinyurl.com/29fqxpgsOrganic Synthesis via Irradiation and Warming of Ice Grains in the Solar Nebula: https://tinyurl.com/262ln3vyOrigin and evolution of the genetic code: the universal enigma: https://tinyurl.com/28fp5xu4Spontaneous formation and base pairing of plausible prebiotic nucleotides in water: https://tinyurl.com/2c2n655rSpontaneous network formation among cooperative RNA replicators: https://tinyurl.com/ycwk6s3rThe Genetics of Vitamin C Loss in Vertebrates: https://tinyurl.com/224hum2aWhere did bone come from? An overview of its evolution: https://tinyurl.com/24w9azexThe human cell count and size distribution: https://tinyurl.com/2d2qsq3lWhat is the Most Recent Manuscript Count for the New Testament?: https://tinyurl.com/28kcvamgAll my various links can be found here:http://links.vicedrhino.comThis content is CAN credentialed, which means you can report instances of harassment, abuse, or other harm on their hotline at (617) 249-4255, or on their website at creatoraccountabilitynetwork.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/viced-rhino-the-podcast--4623273/support.
In this episode of the Epigenetics Podcast, we talked with Mo Motamedi from the Center for Cancer Research at Massachusetts General Hospital about his work on RNA-mediated epigenetic regulation. The Interview starts with Dr. Motamedi sharing his personal journey into the realm of biology, sparked by a familial inclination towards science and a challenge to excel in a field that initially felt daunting. His passion was ignited during a genetics class, as he recognized the quantitative nature of the discipline amidst the evolution of modern techniques like qPCR and high-throughput sequencing. Dr. Motamedi goes on to articulate the importance of understanding the interplay between genetics and broader biological systems, emphasizing that an insightful grasp of evolution is vital for decoding cellular mechanisms. He reflects on his time in a postdoctoral lab under Danish Moazet, investigating RNA interference (RNAi) and its unexpected nuclear roles, contributing significantly to the understanding of how RNAi is involved in gene silencing via chromatin interaction. As his narrative unfolds, Dr. Motamedi provides deep insights into his own lab's work, which focuses on the establishment and maintenance of epigenetic states and their implications in cancer epigenetics. He discusses groundbreaking discoveries related to RNAi and heterochromatin, detailing experiments that unveil how specific proteins contribute to transcriptional and post-transcriptional gene silencing. A pivotal theme emerges: the complex dynamics of genome evolution and chromatin organization can be reshaped under various biological contexts, including the quiescent state of cells under stress. Moreover, the discussion traverses recent publications from Dr. Motamedi's lab, revealing how they identify long non-coding RNAs that function as silencers at centromeres, an essential mechanism that aids in the establishment of heterochromatin independently of RNAi. His findings advocate for the idea that well-structured genome organization can lead to more efficient gene regulation, which can also be crucial in therapeutic contexts for various cancers. References Motamedi, M. R., Hong, E. J., Li, X., Gerber, S., Denison, C., Gygi, S., & Moazed, D. (2008). HP1 proteins form distinct complexes and mediate heterochromatic gene silencing by nonoverlapping mechanisms. Molecular cell, 32(6), 778–790. https://doi.org/10.1016/j.molcel.2008.10.026 Joh, R. I., Khanduja, J. S., Calvo, I. A., Mistry, M., Palmieri, C. M., Savol, A. J., Ho Sui, S. J., Sadreyev, R. I., Aryee, M. J., & Motamedi, M. (2016). Survival in Quiescence Requires the Euchromatic Deployment of Clr4/SUV39H by Argonaute-Associated Small RNAs. Molecular cell, 64(6), 1088–1101. https://doi.org/10.1016/j.molcel.2016.11.020 Joh, R. I., Lawrence, M. S., Aryee, M. J., & Motamedi, M. (2021). Gene clustering drives the transcriptional coherence of disparate biological processes in eukaryotes. Systems Biology. https://doi.org/10.1101/2021.04.17.440292 Related Episodes Evolutionary Forces Shaping Mammalian Gene Regulation (Emily Wong) Chromatin Evolution (Arnau Sebé-Pedrós) The Role of lncRNAs in Tumor Growth and Treatment (Sarah Diermeier) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com
Słuchasz nas regularnie? Zajrzyj na https://patronite.pl/radionaukowe***Ze szkoły mniej więcej pamiętamy obrazek: obszerna komóreczka otoczona błoną, w środku jądro, jakieś mitochondrium, całość pływa wygodnie w cytoplazmie. To oczywiście uproszczone przedstawienie. Podstawowa zmiana jest taka, że w komórkach nic wygodnie nie pływa: elementów jest bardzo dużo i są ciasno upchane. Ma to swoją funkcję. – Dzięki temu różne cząsteczki mogą ze sobą w uporządkowany sposób oddziaływać – wyjaśnia gość odcinka, dr Takao Ishikawa z Wydziału Biologii Uniwersytetu Warszawskiego. – Współczesne badania pokazują, że w komórce jest bardzo, bardzo tłoczno – dodaje. Rozmawiamy o niesamowicie złożonym i dopracowanym ewolucyjnie mechanizmie, jakim jest komórka.W jądrze komórkowym informacja genetyczna zostaje poddana transkrypcji, czyli przepisana na cząsteczki RNA. Nieduży fragment DNA rozwija się, przepisuje do RNA i zwija z powrotem. – Zapis genetyczny w każdej komórce w zasadzie jest taki sam, ale w zależności od tego, w jakiej tkance dana komórka się znajduje, to stopień superskrętów w różnych obszarach materiału genetycznego może być różny, co się przekłada właśnie na to, że różne geny są aktywne w jednej tkance, a inne w drugiej tkance – tłumaczy mój gość. Cząsteczki mRNA wydostają się z jądra komórkowego i trafiają do rybosomów, gdzie stykają się z innym rodzajem RNA: transferowym, tRNA. W rybosomie poszczególne aminokwasy łączą się w łańcuch białkowy, który odzwierciedla informację genetyczną. Komórki bowiem na co dzień są bardzo zajęte produkowaniem białek.W odcinku omawiamy też oczywiście pozostałe elementy komórki, a jest ich sporo. Będzie o błonie komórkowej, mitochondriach, retikulum i aparacie Golgiego. Dowiecie się też, jaka komórka w ludzkim ciele jest największa, a jaka najmniejsza, dlaczego nie do końca da się stworzyć sztuczną komórkę do badań i skąd wiemy, że mitochondria mają pochodzenie bakteryjne. Posłuchajcie, zachwycicie się swoim organizmem!
In today's episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In our exclusive interview, Dr Liu discussed key efficacy and safety findings from the phase 2 VISION trial (NCT02864992) that led to the FDA approval of tepotinib for this indication; the comparable response rates seen between tissue and liquid biopsy results, as well as across NSCLC treatment lines; and the importance of early biomarker testing, including RNA sequencing, to identify actionable mutations and optimize treatment.
Rebecca Culshaw Smith's Substack, “The Real AIDS Epidemic,” highlights core criticisms of mainstream HIV/AIDS theory, medical testing, pharmaceutical practices, and challenges to scientific orthodoxy. Based on her popular posts, interviews, and thematic content, these are 20 of the most important ideas advanced on her platform: 1. Questioning the existence of HIV as a unique virus, arguing that classic virological isolation (Koch's postulates) has not been fulfilled. 2. Highlighting the non-specificity and cross-reactivity of HIV antibody tests, leading to potential misdiagnosis. 3. Criticism of “viral load” PCR tests for not detecting whole pathogens but only RNA fragments. 4. Noting the shifting criteria for HIV test positivity over time, calling diagnostic standards into question. 5. Documenting long-term “non-progressors” and “elite controllers” who remain healthy without antiretroviral therapy. 6. Raising awareness of AIDS-defining illnesses in HIV-negative individuals and questioning causality. 7. Arguing that hazard from AIDS medications (e.g., AZT, Truvada, Prep) may outweigh their benefits, especially due to their toxicity and inconsistent trial results. 8. Critique of the marketing and deployment of pre-exposure prophylaxis (Prep), calling it a pharmaceutical “scandal” targeting people not at significant risk. 9.Exploring how COVID-19 public health narratives mirror what she views as deception and fear tactics from the AIDS era. 10. Disputing the epidemiological narrative that AIDS is globally caused by a single infectious agent, and highlighting massive regional/demographic inconsistencies. 11. Exposing groupthink, censorship, and reputational shaming used against scientists questioning the HIV/AIDS paradigm. 12. Emphasizing failures of antiretroviral therapy in preventing disease progression for many patients. 13.. Explaining the statistical and mathematical problems in foundational HIV/AIDS research and the “shaky foundation” of guiding studies. 14. Arguing that AIDS-defining diseases may often reflect toxicity, malnutrition, or existing comorbidities, not a distinct viral syndrome. 15. Linking historical and social factors (such as drug use, pharmaceutical incentives) to the creation and persistence of the HIV/AIDS establishment. 16. Alerting readers to issues of false positive antenatal screening and broader concerns about mass diagnostic testing in medicine. 17. Suggesting that “virus-like particles” in the body are misidentified as pathogens, not proof of HIV's existence. 18. Forecasting that advances in AI and technology may help overturn scientific “consensus” by increasing transparency and debate. 19 Publicly refuting hit pieces and attempts to “cancel” her work as ideological suppression, not science. 20.Advocating for a return to fundamental scientific rigor and genuine skepticism in medical research, especially around virology and public health narratives. These topics synthesize her core objections to HIV/AIDS orthodoxy and frame her Substack as a point of dissent and critique against modern medical paradigms and their social consequences.
In this JCO Precision Oncology Article Insights episode, Dr. Jiasen He summarizes JCO PO article "Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer" by Hua Zhong et al. TRANSCRIPT Jiasen He: Hello and welcome to the JCO Precision Oncology Article Insights. I am your host, Jiasen He, and today we will be discussing the JCO Precision Oncology article, "Synthetic Lethal Co-mutations in DNA Damage Response Pathway Predict Response to Immunotherapy in Pan-Cancer" by Dr. Zhang and colleagues. Immunotherapy has emerged as a groundbreaking treatment option for many types of cancer. However, the overall response rate to immunotherapy is low, around 10% to 30%. This highlights the critical need to identify which patients are most likely to benefit from immunotherapy. Two of the most extensively studied biomarkers are PD-L1 expression and tumor mutation burden (TMB). High levels of PD-L1 and TMB have been associated with better response to immune checkpoint inhibitors, which are now widely used in clinical practice. The predictive value of these markers is inconsistent across all settings. Some tumors with high PD-L1 or TMB still respond poorly to immunotherapy. One reason is that TMB reflects new antigen production, but recent studies suggest that new antigen levels do not always correlate with tumor immunogenicity. Many new antigens are not effectively recognized by T cells, limiting the immune response. Emerging evidence indicates that mutations in the DNA damage response (DDR) pathway play a critical role in moderating tumor immune interactions. Tumors harboring DDR pathways frequently exhibit increased genome instability, which may enhance their sensitivity to immune checkpoint inhibitors. While all these pathways are under active investigation, the optimal DDR pathway biomarkers for patient selection remain unclear. Notably, tumor cells with a defect in one DDR pathway may acquire greater reliance on alternative DDR pathways. Recent studies suggest that synthetic lethal co-mutations within DDR pathways are associated with immune-inflamed or hot tumor microenvironments. Based on this rationale, Dr. Zhang is investigating if synthetic lethal co-mutations in DDR pathway response pathway can serve as a treatment biomarker for immune checkpoint inhibitors. To address this question, Dr. Zhang and colleagues first utilized SynLethDB 2.0, a comprehensive database that integrated multiple data sets. Synthetic lethal (SL) gene pairs in this resource are identified through both experimental and computational approaches, with confidence scores assigned to each pair. These SL pairs were then mapped to gene sequencing results from several clinical cohorts. SL co-mutation status was defined as positive when both genes in a synthetic lethal pair were mutated. From this, SL co-mutation pairs specifically involving DDR pathway genes were selected. Patients were classified as DDR co-mutation positive if both genes in a synthetic lethal pair, each belonging to the defined DDR pathways, were mutated. In total, 431 DDR-related SL pairs were identified and matched to sequencing data from clinical cohorts. Clinical information was extracted from the cBioPortal, while further analysis of immune infiltration was performed using DNA mutation and RNA expression data from The Cancer Genome Atlas (TCGA) pan-cancer data set. The author first examined the correlation between SL co-mutation status and response to ICI therapy. They discovered that patients with SL co-mutation showed significantly improved outcome to ICI therapy across various clinical cohorts. Notably, in patients who did not receive ICI treatment, patients with SL co-mutation showed markedly compromised overall survival. Further analysis focused on the predictive value of SL co-mutation within DDR pathway genes. The author found that patients with DDR SL co-mutation had a longer overall survival compared to those with mutations in a single DDR gene, implying that SL co-mutations may be more effective biomarkers within the DDR pathway. To explore this further, in the TMB-MSKCC cohort, the author found that patients with DDR co-mutation constituted approximately 20% of various cancer types, including non-small cell lung cancer, melanoma, and bladder cancer. These patients demonstrated significantly better survival outcomes and disease control rates when treated with ICIs compared to DDR co-mutation negative patients. Notably, the TMB level was substantially higher in patients with DDR co-mutation, a finding consistent with data from the Miao-lung cohort. Furthermore, in cohorts not treated with ICIs, patients with DDR co-mutation had a shorter overall survival compared to their counterparts. Upon stratifying by PD-L1 expression, the author observed that patients with DDR co-mutation who were also PD-L1 positive derived the greatest clinical benefit from ICI therapy. Upon analyzing the frequency of co-mutation within the DDR pathway, the authors found that patients with SL co-mutation in the CPF-CPF pathway experienced remarkable survival benefit from ICIs. Within this group, one of the most common co-mutation combinations was TP53-ATM, observed in approximately 45% of cases, which was associated with a better response to ICI therapy. Further analysis of immune cell infiltration revealed that patients with TP53-ATM co-mutation exhibited a distinct tumor immune microenvironment. As the authors stated, the study's main limitation lies in the nature of retrospective analysis, which lacked the control over confounding variables and was subject to non-random sampling. For instance, patients with both SL co-mutations and DDR SL co-mutations exhibited high TMB, and TMB was known to be associated with improved response to ICI therapy itself. So, these findings require validation through prospective studies, and immune infiltration analysis needs confirmation via laboratory experiments. In conclusion, the authors found that patients with SL co-mutations in DDR pathways showed favorable clinical response and prolonged survival following ICI therapy. They also identified TP53-ATM co-mutations as a clinically relevant biomarker for predicting ICI treatment response. Thank you for tuning in to JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Deze week in The Trueman Show: Ewald Stöteler Ewald is al ruim 45 jaar homeopaat en docent, en behoort wereldwijd tot de meest ervaren experts op dit gebied. In dit gesprek deelt hij zijn persoonlijke reis van de oncologie-afdeling in het ziekenhuis naar de diepere wereld van homeopathie. Hij legt uit waarom ziekte volgens hem niet in de materie zit, maar voortkomt uit verstoringen van de levenskracht — en waarom genezing altijd van binnenuit moet komen. In deze podcast: ⚡ Zelfgenezend vermogen “De dokter kan mij niet beter maken. De homeopaat ook niet. Ik kan alleen mezelf beter maken.”
In this episode of Founded & Funded, Madrona Investor Joe Horsman sits down with Jeff Leek and Rob Bradley, co-founders of Synthesize Bio, a foundation model company for biology that's unlocking experiments researchers could never run in the lab. Jeff, chief data officer at the Fred Hutch Cancer Center, and Rob, the McIlwain Family endowed chair in data science, share: •Why a startup the right fit for generative genomics •How generative genomics could reshape research, drug trials, and more •Why RNA is the right starting point for a generative AI model in biology •What this breakthrough means for the future of drug development •Why now is biology's “ChatGPT moment” •What makes Synthesize a true foundation model for biology (not a point solution) Whether you're a founder, biotech innovator, or AI researcher, this is a must-listen conversation about the intersection of AI, biology, and the future of medicine. Transcript:https://www.madrona.com/the-future-of-biology-is-generative-inside-synthesize-bios-rna-ai-model Chapters: (2:00) – Why a Foundation Model for Biology? (5:00) – The Case for RNA (7:00) – Biology's Large Language Model Analogy (9:00) – Solving Impossible Problems (11:00) – Validation & Testing (14:00) – Balancing Big Picture & Specific Biology (15:00) – Why a Company, Not Just a Lab (16:00) – Has Biology Had Its “ChatGPT Moment”? (19:00) – The Data Challenge (23:00) – Real-World Use Cases (26:00) – How Research Will Look in 10 Years (28:00) – Increasing the Odds of Discovery (29:00) – Clinical Trials & Precision Medicine (31:00) – Access & Next Steps
Listen & subscribe on Apple, Spotify, YouTube, and other platforms. Welcome everyone to the weekly San Diego Tech News! I'm Neal Bloom from Rising Tide Partners and the Tacos and Tech Podcast. My co-host in this episode is Fred Grier, journalist and author of The Business of San Diego substack. He covers the ins-and-outs of the startup world including breaking news, IPOs, fundraising rounds, and M&A through his newsletter. Before we dive in, we wanted to thank and ask our listeners to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup Community! 9/19 Broader Defense Tech: Harpoon x Firestorm Mixer Debrief El Segundo Defense Tech Mixer Debrief Firestorms Labs opens 60,000 SFT Facility in Mira Mesa Biotech: Treeline Biosciences emerges from stealth with $200M backed by ARCH Venture. Arnatar Therapeutics focused on precision RNA therapies emerges from stealth. Debut Bio raises and expands to Asia Yatiri - acquired another startup Luna Diabetes raises a Series A Curated Events List – For full list – check The Social Coyote Sept 26 - Defense Tech Gathering Oct 3-5 Startup Weekend Oct 6-10 SD Startup Week
Breastmilk is Dynamic Cellular and transcriptional diversity over the course of human lactation This recent 2022 paper in the Proceedings of the National Academy of Sciences by Dr. Nyqiust and colleagues is a site for sore eyes. It offers a remarkable, high-resolution portrait of how the cellular landscape of human breast milk (hBM) shifts over time. The authors capture something both scientifically rich and uniquely human: the dynamic, living composition of milk as it adapts to the changing needs of mother and child. The abstract: "Human breast milk is a dynamic fluid that contains millions of cells, but their identities and phenotypic properties are poorly understood. We generated and analyzed single-cell RNA-sequencing (scRNA-seq) data to characterize the transcriptomes of cells from hBM across lactational time from 3 to 632 d postpartum in 15 donors. We found that the majority of cells in hBM are lactocytes, a specialized epithelial subset, and that cell-type frequencies shift over the course of lactation, yielding greater epithelial diversity at later points. Analysis of lactocytes reveals a continuum of cell states characterized by transcriptional changes in hormone-, growth factor-, and milk production-related pathways. Generalized additive models suggest that one subcluster, LC1 epithelial cells, increases as a function of time postpartum, daycare attendance, and the use of hormonal birth control. We identify several subclusters of macrophages in hBM that are enriched for tolerogenic functions, possibly playing a role in protecting the mammary gland during lactation. Our description of the cellular components of breast milk, their association with maternal–infant dyad metadata, and our quantification of alterations at the gene and pathway levels provide a detailed longitudinal picture of hBM cells across lactational time. This work paves the way for future investigations of how a potential division of cellular labor and differential hormone regulation might be leveraged therapeutically to support healthy lactation and potentially aid in milk production." (Nyquist et. al. 2022) And more information on breastmilk immunology and a recipe. Dr. M
Earlier this year, when the world learned the news of baby KJ successfully undergoing the first personalized genetic treatment, it represented a milestone for researchers and patients. But behind this scientific feat there’s the story of the technology that made it possible, CRISPR, and one of the key pioneers behind it — Jennifer Doudna. Evan sits down with Walter Isaacson to understand how Doudna’s upbringing in Hilo, Hawaii influenced her trajectory as a gene editing scientist. And how the history of gene editing might have started with understanding DNA, but soon after, it became clear the real secret lay with its underrated sibling molecule, RNA.See omnystudio.com/listener for privacy information.
TWiV re-issues our 100th episode which featured a discussion of viruses with David Baltimore, an exemplary scientist and Vincent's exemplary mentor, who passed on 6 September 2025. Hosts: Vincent Racaniello, Alan Dove, and Rich Condit Guest: David Baltimore Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV David's early papers on poliovirus and mengovirus RNA synthesis Reverse transcriptase found by Baltimore and Temin (pdfs) Nobel Prize in Physiology or Medicine 1975 The David Baltimore asteroid belt Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
In this episode of the Epigenetics Podcast, we talked with Arnau Sebé-Pedrós from the Center for Genomic Regulation in Barcelona about his work on chromatin evolution. The Interview starts by examining specific research findings, including his seminal 2018 paper demonstrating whole-organism single-cell transcriptomics to map larval and adult cell types in the model organism Nematostella vectensis. Dr. Sebe-Pedros recounted the challenges and triumphs faced when delving into single-cell studies of non-model organisms, revealing the innovative strategies employed in the lab to overcome these hurdles. Shifting gears, we touched upon his work comparing cell types and molecular pathways in reef-building corals through single-cell RNA sequencing, contributing to our understanding of evolutionary conservation and divergence within the cnidarian lineage. We discussed how this comparative approach not only adds to knowledge about coral biology but also enhances methodological frameworks in ecological studies. In addition, Dr. Sebe-Pedros shared insights into ongoing efforts to reconstruct eukaryotic chromatin evolution using comparative proteomics and genomics analysis, as well as the mechanisms of genomic regulation in various species. His reflections on the sharing of experimental insights across research groups illustrated the collaborative spirit prevalent in the scientific community, particularly regarding endeavors like the Biodiversity Cell Atlas consortium aimed at expanding single-cell efforts across the tree of life. The episode culminated with Dr. Sebe-Pedros's thoughts on the revolutionary impact of functional genomic technologies and the vast potential they hold for answering longstanding questions in evolutionary biology. With an emphasis on epigenetics, he defined this field as encompassing any information not encoded directly in the DNA, especially in its role in establishing cell identity and differentiation. References https://www.biodiversitycellatlas.org Sebé-Pedrós, A., Saudemont, B., Chomsky, E., Plessier, F., Mailhé, M. P., Renno, J., Loe-Mie, Y., Lifshitz, A., Mukamel, Z., Schmutz, S., Novault, S., Steinmetz, P. R. H., Spitz, F., Tanay, A., & Marlow, H. (2018). Cnidarian Cell Type Diversity and Regulation Revealed by Whole-Organism Single-Cell RNA-Seq. Cell, 173(6), 1520–1534.e20. https://doi.org/10.1016/j.cell.2018.05.019 Sebé-Pedrós, A., Chomsky, E., Pang, K., Lara-Astiaso, D., Gaiti, F., Mukamel, Z., Amit, I., Hejnol, A., Degnan, B. M., & Tanay, A. (2018). Early metazoan cell type diversity and the evolution of multicellular gene regulation. Nature ecology & evolution, 2(7), 1176–1188. https://doi.org/10.1038/s41559-018-0575-6 Kim, I.V., Navarrete, C., Grau-Bové, X. et al. Chromatin loops are an ancestral hallmark of the animal regulatory genome. Nature 642, 1097–1105 (2025). https://doi.org/10.1038/s41586-025-08960-w Related Episodes Evolutionary Epigenetic Clocks and Epigenetic Inheritance in Plants (Frank Johannes) Neuroepigenetic Mechanisms and Primate Epigenome Evolution (Boyan Bonev) Transposable Elements in Gene Regulation and Evolution (Marco Trizzino) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com
The potential breakthrough in RNA vaccine technology has been increasingly discussed on social media. This episode looks at one promising study and its early, early results so far. UF GBM study: https://doi.org/10.1016/j.cell.2024.04.003 RNA Treatment Vaccine Review: https://doi.org/10.1002/ctm2.1384
Joe Untamed tackles two urgent battles shaping America's future: the rise of radical Islamist influence and the war over truth in public health. Robert Spencer, renowned scholar and director of Jihad Watch, joins us to break down the growing presence of Islamist ideology in U.S. communities—from mass gatherings in Michigan to city councils now dominated by Muslim politicians. What does this mean for American law, culture, and national security? Spencer peels the onion back on the elites enabling this transformation and warns what's at stake if we continue down this path unchecked. Then, Dr. Robert Malone—the original inventor of mRNA vaccine technology—returns to reveal how entrenched bureaucrats and Big Pharma allies are weaponizing science against the American people. With new developments inside HHS and RFK Jr.'s sweeping reforms, Malone exposes the deep state's retaliation, the dangers of indemnifying industries like RNA pesticides, and the long-term health consequences hidden from public view. From vaccine schedules to regulatory corruption, his insights strike at the heart of America's medical and political crises. Together, Spencer and Malone highlight the same underlying truth: powerful elites, whether in religion, government, or corporate boardrooms, are eroding American freedom from within. This is not just about foreign threats or public health—it's about the survival of liberty itself. Tonight's show is a wake-up call, offering clarity, urgency, and solutions for anyone ready to stand against the forces trying to reshape America in their image.
Congressman Ralph Norman, who is now a candidate for governor of South Carolina, shares his motivations for transitioning from Congress to the gubernatorial race and discusses his vision for the state, including infrastructure improvements, term limits, and combating corruption. Congressman Norman also reflects on the successes of Florida under Governor Ron DeSantis and the need for South Carolina to adopt similar strategies. Dr. Peter McCullough, chief scientific officer at The Wellness Company, discusses the potential links between COVID-19 vaccines and the increase in rapid cancer cases. We explore the implications of messenger RNA technology, the influence of pharmaceutical advertising on medical reporting, and the emerging role of Ivermectin in cancer research. Aaron Withe, CEO of the Freedom Foundation, reveals the troubling trends stemming from the significant influence of teachers unions on American culture and politics. Kasim Khan takes a closer look at the dire situation of his father, former Pakistani Prime Minister Imran Khan, who has been imprisoned under disturbing conditions. Khan shares the harrowing details of his father's incarceration, the struggle for human rights, and the international efforts to secure his release. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2025 Ivy Podcast Discovery LLC
